Lay Description

This phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab may work better in treating patients with TFE/translocation renal cell carcinoma compared to standard treatment, including surgery, chemotherapy, or immunotherapy.


  • Urinary Tract and Kidney
  • Cancers and Other Neoplasms
  • Renal Cell Carcinoma
IRB Number
NCT Number
Open to Enrollment


Eligible Ages
Over 12 Months
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact

Regulatory Point of Contact
Jaclyn Hung
+1 (210) 450-5358

Regulatory Point of Contact
Anne-Marie Langevin
(210) 567-7460

Principal Investigator
Anne-Marie Langevin